AEON AEON Biopharma, Inc.

$0.28

AEON Biopharma, Inc. (AEON) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.2% since its last earnings release on August 12, 2026.

AEON Biopharma Reported Earnings
Wednesday, August 12, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.07)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.27

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AEON Biopharma, Inc.

AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif.

Sector

Healthcare

Industry

Biotechnology